ArticleEuropean journal of neurology2026
Sleep Disorders in Medication-Overuse Headache: Prevalence and Associated Factors.
Article in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSleep disorders can exacerbate headache burden, yet their prevalence and reversibility in medication-overuse headache (MOH) remain unexplored. We aimed to evaluate sleep disorders and associated factors in MOH patients compared with controls, and to assess outcomes following headache treatment.
methodsThis prospective case-control study was conducted at a specialised headache center. Patients aged ≥ 18 years with MOH (n = 171; mean age 43.3 years; 81.9% female; migraine 64.9%; tension-type headache 35.1%) and age- and sex-matched headache controls without MOH (n = 173; mean age 41.4 years; 74.6% female; migraine 57.8%; tension-type headache 42.2%) underwent semi-structured interviews and standardised assessments including semi-structured interviews, validated questionnaires, headache and sleep calendars and polysomnography when indicated. Follow-up assessments were performed after headache treatment in 87 MOH patients (mean 24.2 months) and 70 controls (mean 26.4 months).
resultsChronic insomnia was more prevalent in MOH than in controls (60.2% vs. 47.4%; OR 1.7, 95% CI 1.1-2.6, p = 0.03), as was restless legs syndrome (37.4% vs. 22.0%; OR 2.1, 95% CI 1.3-3.4, p = 0.003). Factors associated with chronic insomnia in MOH included nocturnal headache (OR 2.0), nighttime analgesic use (OR 2.5), overweight (OR 2.7), and arterial hypertension (OR 2.6). Following treatment, chronic insomnia decreased to 33.3% and restless legs syndrome to 14.9% (both p < 0.001), paralleling reductions in headache frequency and analgesic use.
conclusionsThis is the first study to demonstrate high sleep disorder prevalence in MOH and its reversibility following headache treatment. Early screening for sleep disorders in MOH patients is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.